Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2015
Efficacy, safety, and outcomes in 17 pediatric cases treated with the free radical scavenger edaravone.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Nakamoto Hidetoshi, Aihara Yasuo, Yamaguchi Koji, Kawamata Takakazu, Okada Yoshikazu
Аннотация
SUBJECTS: Edaravone is a free radical scavenger with brain protection properties and is recommended by "The Japanese Guidelines for the Management of Stroke 2009" for administration to adult patients, in whom it has been shown to improve neurological deficits after cerebral infarction. However, its dosage and effects have not yet been established in children.
METHODS: Seventeen pediatric patients with cerebral ischemia were administered edaravone at a dose based on body weight from the standard dose given to adults. Functional outcomes were evaluated using mRS and PSOM (modified ranking scale and pediatric stroke outcome scale, respectively).
RESULTS: Immediate post-treatment results were mostly positive, with no liver or renal complications. In some cases, neurological symptoms markedly improved after the administration of edaravone.
CONCLUSIONS: The efficacy of edaravone has not yet been examined in pediatric patients. The results of the present study suggest that edaravone has potential in the treatment of children safely with promising results similar to those in adults.
METHODS: Seventeen pediatric patients with cerebral ischemia were administered edaravone at a dose based on body weight from the standard dose given to adults. Functional outcomes were evaluated using mRS and PSOM (modified ranking scale and pediatric stroke outcome scale, respectively).
RESULTS: Immediate post-treatment results were mostly positive, with no liver or renal complications. In some cases, neurological symptoms markedly improved after the administration of edaravone.
CONCLUSIONS: The efficacy of edaravone has not yet been examined in pediatric patients. The results of the present study suggest that edaravone has potential in the treatment of children safely with promising results similar to those in adults.